相关实验视频
Updated: Jul 12, 2025

08:35
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
7.9K
为选择性破坏Beclin 1与Bcl-2结合的结构洞察力
Yun-Zu Pan1,2,3, Qiren Liang2, Diana R Tomchick1
1Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Communications biology
|October 24, 2023
概括
科学家们发现了一种新化合物,可以刺激细胞自,这种细胞过程有利于治疗癌症等疾病. 这种化合物,35,准Bcl-2以增强自而不会触发亡,提供了一个有前途的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 自刺激对癌症和神经退行等疾病具有治疗潜力.
- Bcl-2 是自的关键抑制剂,与贝克林1 BH3 域结合.
- 抑制Bcl-2可以促进自,但也可以通过释放像Bax这样的亲亡因子来诱导亡.
研究的目的:
- 阐明化合物35与Bcl-2相互作用的结构基础.
- 要了解35化合物如何选择性地抑制贝克林1/Bcl-2结合,而不是巴克斯/Bcl-2结合.
- 为了指导新型自刺激疗法的设计,减少了亡的副作用.
主要方法:
- 核磁共振 (NMR) 谱学被用来确定Bcl-2与化合物35复合的结构.
- 生物化学试验被用来比较化合物35与Beclin 1和Bax的结合亲和力.
主要成果:
- 核磁共振结构显示,该化合物35与Bcl-2的BH3结合槽上的一个不同的位点结合.
- 与Bax/Bcl-2结合相比,化合物35显示出比克林1/Bcl-2结合的更强大的抑制.
- 化合物35的结合部位部分与已知的Bcl-2抑制剂部位重叠,但独特地调解与Beclin 1的相互作用.
结论:
- 化合物35的独特结合模式为开发选择性自增强剂提供了结构基础.
- 针对Bcl-2上的Beclin 1相互作用部位提供了一种在不诱导亡的情况下刺激自的策略.
- 这项研究为设计更安全,更有效的自相关疾病疗法铺平了道路.
相关概念视频
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Selectins
3.3K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K
Pinching-off of Coated Vesicles
3.2K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
3.2K

